19.80

7.48% -1.60

After Hours: 19.00 -0.80 -4.04%

Travere Therapeutics Inc (TVTX)

Overview News Price History Option Chain Financials Why TVTX Down? Discussions Forecast Stock Split

Travere Therapeutics Inc stock is traded at $19.80, with a volume of 1.49M. It is down -7.48% in the last 24 hours and down -2.08% over the past month. Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.

Previous Close:

$21.40

Open:

$21.44

24h Volume:

1.49M

Relative Volume:

1.05

Market Cap:

$1.85B

Revenue:

$203.45M

Net Income/Loss:

$-351.45M

P/E Ratio:

-4.3516

EPS:

-4.55

Net Cash Flow:

$-369.41M

1W Performance:

-6.74%

1M Performance:

-2.08%

6M Performance:

+106.25%

1Y Performance:

+151.59%

1-Day Range:

$19.60

$21.98

1-Week Range:

$19.60

$21.98

52-Week Range:

$5.12

$25.29

Travere Therapeutics Inc Stock (TVTX) Company Profile

Name

Travere Therapeutics Inc

Sector

Healthcare (1189)

Industry

Biotechnology (682)

Phone

888-969-7879

Address

3611 VALLEY CENTRE DR, SAN DIEGO

Employee

385

Twitter

Next Earnings Date

2024-10-31

Latest SEC Filings

TVTX's Discussions on Twitter

Compare TVTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TVTX Travere Therapeutics Inc	19.80	1.85B	203.45M	-351.45M	-369.41M	-4.55
VRTX Vertex Pharmaceuticals Inc	483.31	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	684.87	75.07B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	622.61	37.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	243.53	31.79B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	111.56	27.34B	3.30B	-501.07M	1.03B	-2.1146

Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Oct-21-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-09-24	Upgrade	Guggenheim	Neutral → Buy
Mar-27-24	Downgrade	Guggenheim	Buy → Neutral
Dec-05-23	Upgrade	Citigroup	Neutral → Buy
Nov-20-23	Initiated	Citigroup	Neutral
Sep-22-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-06-23	Resumed	Evercore ISI	Outperform
Jul-21-23	Initiated	JP Morgan	Overweight
Jun-07-23	Resumed	Piper Sandler	Neutral
May-22-23	Initiated	TD Cowen	Outperform
May-05-23	Upgrade	Bryan Garnier	Sell → Neutral
Mar-01-23	Initiated	Guggenheim	Buy
Feb-21-23	Upgrade	Wedbush	Neutral → Outperform
Dec-14-22	Initiated	Stifel	Hold
Dec-05-22	Initiated	Wells Fargo	Overweight
Sep-21-22	Initiated	Bryan Garnier	Sell
Jul-14-22	Resumed	Canaccord Genuity	Buy
Mar-31-22	Initiated	Piper Sandler	Overweight
Feb-28-22	Initiated	H.C. Wainwright	Buy
May-26-21	Downgrade	Wedbush	Outperform → Neutral

View All

Travere Therapeutics Inc Stock (TVTX) Latest News

Mar 02, 2025

When the Price of (TVTX) Talks, People Listen - Stock Traders Daily

Mar 02, 2025

Feb 28, 2025

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat

Feb 28, 2025

20,749 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Purchased by Ieq Capital LLC - MarketBeat

Feb 28, 2025

Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $35.00 at Citigroup - MarketBeat

Feb 28, 2025

Feb 27, 2025

Can Ligand's Triple FDA Wins Offset Its $31M Q4 Loss? Revenue Jumps 52% - StockTitan

Feb 27, 2025

Q1 EPS Estimate for Travere Therapeutics Lowered by Analyst - MarketBeat

Feb 27, 2025

Impax Asset Management Group plc Purchases New Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

Feb 27, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Feb 27, 2025

Feb 25, 2025

Travere Therapeutics' (TVTX) Overweight Rating Reaffirmed at Cantor Fitzgerald - MarketBeat

Feb 25, 2025

Feb 24, 2025

Analyst Expectations For Travere Therapeutics's Future - Benzinga

Feb 24, 2025

Travere Therapeutics to Participate at Upcoming Investor Conferences - The Manila Times

Feb 24, 2025

Can Travere's March Conference Blitz Signal Major Development Updates? 4 Key Events to Watch - StockTitan

Feb 24, 2025

Citi raises Travere Therapeutics price target to $35, maintains buy By Investing.com - Investing.com Canada

Feb 24, 2025

Citi raises Travere Therapeutics price target to $35, maintains buy - Investing.com India

Feb 24, 2025

Travere Therapeutics (NASDAQ:TVTX) Posts Quarterly Earnings Results - MarketBeat

Feb 24, 2025

Feb 23, 2025

Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease Drug - MSN

Feb 23, 2025